881190-18-7

Basic information

• Product Name: 6,7-difluoro-2,3-dihydro-1H-inden-1-one
• Synonyms: 6,7-difluoro-2,3-dihydro-1H-inden-1-one;6,7-Difluoro-1-indanone
• CAS NO: 881190-18-7
• Molecular Formula: C9H6F2O
• Molecular Weight: 168.1401464
• Mol File: 881190-18-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 6,7-difluoro-2,3-dihydro-1H-inden-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: 6,7-difluoro-2,3-dihydro-1H-inden-1-one(881190-18-7)
• EPA Substance Registry System: 6,7-difluoro-2,3-dihydro-1H-inden-1-one(881190-18-7)

Safety Data

• Hazardous Substances Data: 881190-18-7(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
6,7-difluoro-2,3-dihydro-1H-inden-1-one is used as a building block in organic synthesis for its ability to serve as a versatile starting material for the creation of various organic compounds.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 6,7-difluoro-2,3-dihydro-1H-inden-1-one is utilized as a key intermediate in the development of new drugs due to its potential biological activities and its compatibility with other reagents and solvents, facilitating medicinal chemistry studies.
Used in Medicinal Chemistry Studies:
6,7-difluoro-2,3-dihydro-1H-inden-1-one is employed as a valuable target in medicinal chemistry for exploring its potential biological activities, which can lead to the discovery of new therapeutic agents.

Upstream product

• 161712-75-0 3-(3,4-difluorophenyl)-propanoic acid 
• 161712-76-1 3-(3,4-difluorophenyl)propanoyl chloride 

Relevant articles and documents

SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS

Therapeutic compounds, and methods, compositions, and medicaments related thereto are disclosed herein.

THERAPEUTIC FLUOROETHYLCYANO GUANIDINES

Disclosed herein is compound having a formula as described herein. Therapeutic methods, compositions, and medicaments related thereto are also disclosed.

CYCLIC AMINE DERIVATIVE OR SALT THEREOF

Provided are compounds which are an NMDA antagonist having a broad safety margin and are useful as a treating agent or a preventing agent for Alzheimer's disease, cerebrovascular dementia, Parkinson's disease, ischemic apoplexy, pain, etc. Concretely prov

Indanylidenes. 1. Design and synthesis of (E)-2-(4,6-difluoro-1-indanylidene)acetamide, a potent, centrally acting muscle relaxant with antiinflammatory and analgesic activity

The design of rigid cyclic analogues derived from cinnamamide 1, (E)-N-cyclopropyl-3-(3-fluorophenyl)prop-2-enamide, and β-methylcinnamamide 2, (E)-N-cyclopropyl-3-(3-fluorophenyl)but-2-enamide, has led to the discovery of the potent, centrally acting muscle relaxant (E)-2-(4,6-difluoro-1-indanylidene)acetamide, 17. Compound 17 also possesses potent antiinflammatory and analgesic activity. This paper describes the synthesis and the muscle relaxant, antiinflammatory, and analgesic structure-activity relationships of 17 and 67 of its analogues. Compound 17 has been taken into phase I clinical trials.